Media ReleasesInnate Immunotherapeutics

View All Innate Immunotherapeutics News


Innate Immunotherapeutics, Bioshares Edition 692

Innate Completes Dosing in Phase IIb MS Trial

Innate Immunotherapeutics (IIL: $0.77) has completed dosing the 93 patients participating in its Phase IIb secondary progressive multiple sclerosis (SPMS) trial. Results are now due in late August or early September with the possibility of earlier topline results.

Extensive Assessments in Study Protocol

What needs to be noted with this trial is the extensive assessments of patients that have been incorporated into the study protocol. Two thirds of the patients in the study were treated with the company's drug candidate, MIS416, on a weekly basis for 12 months. The remaining third received a weekly placebo injection.


For further information please download PDF attached:
Download this document